Modality
Fusion Protein
MOA
MALT1i
Target
IL-17A
Pathway
Sphingolipid
CLLMM
Development Pipeline
Preclinical
~Feb 2013
→ ~May 2014
Phase 1
~Aug 2014
→ ~Nov 2015
Phase 2
~Feb 2016
→ ~May 2017
Phase 3
Aug 2017
→ Dec 2031
Phase 3Current
NCT03948449
1,230 pts·MM
2021-10→2027-11·Terminated
NCT03123563
870 pts·CLL
2020-04→2031-12·Terminated
NCT06920423
1,093 pts·MM
2018-08→TBD·Active
+1 more trial
5,689 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-11-191.6y awayPh3 Readout· MM
2031-12-255.7y awayPh3 Readout· CLL
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Not yet…
P3
Active
P3
Termina…
P3
Termina…
Catalysts
Ph3 Readout
2027-11-19 · 1.6y away
MM
Ph3 Readout
2031-12-25 · 5.7y away
CLL
ActiveTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03948449 | Phase 3 | MM | Terminated | 1230 | EDSS |
| NCT03123563 | Phase 3 | CLL | Terminated | 870 | Biomarker |
| NCT06920423 | Phase 3 | MM | Active | 1093 | PASI75 |
| NCT03278770 | Phase 3 | MM | Not yet recr... | 2496 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| ITC-6153 | Intra-Cellular | Phase 3 | KRASG12C |